

Studer Jacqueline  
Form 4  
August 23, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Studer Jacqueline

2. Issuer Name and Ticker or Trading Symbol  
IDEXX LABORATORIES INC /DE [IDXX]

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)

(Last) (First) (Middle)  
ONE IDEXX DRIVE  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
08/21/2018

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
CVP, Gen. Counsel & Secretary

WESTBROOK, ME 04092

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  | Code                           | V   | Amount (A) or (D) Price   |  |   |
| Common Stock                    | 08/21/2018                           |  | M                              |   | 9,400 A \$ 67.85  | 17,034   | D   |
| Common Stock                    | 08/21/2018                           |  | M                              |   | 2,219 A \$ 141.6  | 19,253   | D   |
| Common Stock                    | 08/21/2018                           |  | S                              |   | 5,549 D \$ 243.359 (1)  | 13,704   | D   |
| Common Stock                    | 08/21/2018                           |  | S                              |   | 2,806 D \$ 244.1514 (2)   | 10,898   | D   |
| Common Stock                    | 08/21/2018                           |  | S                              |   | 3,264 D \$ 245.0634   | 7,634  | D   |



## Edgar Filing: Studer Jacqueline - Form 4

(1) Represents the weighted average sales price of the shares sold ranging from a low of \$243.00 to a high of \$243.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

(2) Represents the weighted average sales price of the shares sold ranging from a low of \$244.00 to a high of \$244.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

(3) Represents the weighted average sales price of the shares sold ranging from a low of \$245.00 to a high of \$245.13 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

(4) Grant of option to buy 22,027 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2017.

(5) Grant of option to buy 10,386 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2018.

(6) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.